Joe Fletcher | Senior Vice President of Investor Relations |
Dave Ricks | Chairman & Chief Executive Officer |
Anat Ashkenazi | Chief Financial Officer |
Dan Skovronsky | Chief Scientific & Medical Officer |
Anne White | President, Lilly Neuroscience |
Ilya Yuffa | President, Lilly International Lilly |
Mike Mason | President, Lilly Diabetes |
Patrik Jonsson | President of Lilly Immunology & Lilly USA |
Colin Bristow | UBS |
Chris Schott | JPMorgan |
Seamus Fernandez | Guggenheim |
Geoff Meacham | Bank of America |
Tim Anderson | Wolfe Research |
Terence Flynn | Morgan Stanley |
Steve Scala | Cowen |
Louise Chen | Cantor |
Chris Shibutani | Goldman Sachs |
Umer Raffat | Evercore |
Mohit Bansal | Wells Fargo |
Evan Seigerman | BMO |
Trung Huynh | Credit Suisse |
Carter Gould | Barclays |
Andrew Baum | Citi |
Robyn Karnauskas | Truist Securities |
Ladies and gentlemen, thank you for standing by. And welcome to the Lilly Q4 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later we will conduct the question-and-answer session, and instructions will be given at that time. [Operator Instructions] And as a reminder, today's conference is being recorded.